Biopharma Insights - page 10

Legal and Governance Considerations in AI for Drug Discovery: New Paradigms and 2025 Outlook

Just in time for 2025 prediction season, a survey of the emerging AI drug discovery landscape, prepared by Chris Bradbury, has been making the rounds—and with good reason. The survey …

Continue ›››

The AI-driven Development Journey of ISM5411, a Potential Breakthrough Treatment for Inflammatory Bowel Disease

Inflammatory Bowel Disease (IBD), a chronic and debilitating autoimmune disorder that includes ulcerative colitis and Crohn’s disease, impacts millions of lives globally. Characterized by chronic gut inflammation, intestinal barrier dysfunction, …

Continue ›››

The Importance of Accurate Patient Matching for AI Projects

Artificial intelligence (AI) is revolutionizing healthcare by enhancing workflows, enabling earlier diagnoses, and paving the way for personalized care. However, its success depends on accurate patient matching, which ensures data …

Continue ›››

Survey Highlights Critical Need for AI Adoption in Regulatory Affairs Amid Unsustainable Workloads

New research commissioned by ArisGlobal, a provider of life sciences technology solutions, reveals that surging regulatory workloads are forcing life sciences companies to prioritize advanced AI adoption in regulatory affairs …

Continue ›››

What will be the key trends in AI innovation in the Pharmaceutical Industry in 2025?

The pharmaceutical industry is undergoing transformation thanks to artificial intelligence (AI) in particular GenAI. From drug discovery and manufacturing to speeding up clinical trials and improving sales force effectiveness, AI …

Continue ›››

AI Is Key to Democratizing Drug Discovery

Global Pharma R&D Investments Surpass $276 Billion Annually, Exceeding Previous Estimates

A recent study, titled Comprehensive Measurement of Biopharmaceutical R&D Investment, published in Nature Reviews Drug Discovery, reveals that global pharmaceutical R&D expenditures are significantly higher than previously reported. According to …

Continue ›››

The Promise of Chatbots in Clinical Trials

In the rapidly changing field of clinical trials, chatbots are becoming valuable tools for data analysis. These AI-driven conversational agents streamline data collection, boost patient engagement, and enhance the accuracy …

Continue ›››

Even 10 Minutes Matter in Cancer Research

A recent study conducted by Indivumed Therapeutics highlights a crucial, yet often overlooked, factor in cancer research: the cold ischemia time (CIT), or the time it takes to preserve tumor …

Continue ›››

How Enterprise Architecture is Powering Digital Transformation in Healthcare

The healthcare industry is confronting critical challenges including a systemic labour shortage, rising costs (estimated to grow to its highest level in 13 years) and regulatory pressures. In PwC’s 26th …

Continue ›››

UK-based Laverock Therapeutics Expands Gene-Silencing Technology to Tackle Multiple Disease Areas

Laverock Therapeutics, a UK company based at the Stevenage Bioscience Catalyst, is advancing its programmable gene-silencing platform, GEiGS, aimed at simultaneously silencing multiple genes. The technology uses reprogrammed microRNAs (miRNAs)—molecules …

Continue ›››

How AI Makes Telehealth for STIs Smarter and More Accessible

In a recent WHO report, Director-General Dr. Tedros Ghebreyesus raised concerns about the global STI epidemic saying, “HIV, viral hepatitis, and sexually transmitted infections (STIs) continue to pose a major …

Continue ›››